Hexaxim Vaccine is a combined immunization preparation containing Diphtheria Immune Globulin (20 IU), Haemophilus influenzae type b Conjugate Vaccine (12 mcg), Pertussis Toxoid (25 mcg), Tetanus Toxoid (40 IU), and inactivated Poliomyelitis Virus types 1, 2, and 3 with antigen units of 40D, 8D, and 32D respectively. This vaccine is indicated for active immunization against diphtheria, Haemophilus influenzae type b infections, pertussis (whooping cough), tetanus, and poliomyelitis in infants and young children. Hexaxim provides a comprehensive immunological defense by stimulating the production of protective antibodies, thereby reducing the risk of these potentially severe and life-threatening diseases. The vaccine is administered intramuscularly according to recommended immunization schedules, typically starting at 6 weeks of age with subsequent doses at appropriate intervals. Hexaxim’s combination formulation enhances compliance and reduces the number of injections required, improving vaccination coverage. It is contraindicated in individuals with a history of severe allergic reactions to any component of the vaccine or previous dose. Common adverse reactions may include mild local injection site reactions, fever, and irritability. Healthcare providers should assess patient history prior to administration and monitor for any immediate hypersensitivity reactions post-vaccination. Hexaxim is a vital tool in pediatric immunization programs worldwide.